Adaptimmune Therapeutics plc Cash Flow Conversion Efficiency
Adaptimmune Therapeutics plc cash flow conversion efficiency. Based on the latest financial reports, Adaptimmune Therapeutics plc (473A) has a cash flow conversion efficiency ratio of 0.490x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-34.78 Million ≈ $-40.66 Million USD) by net assets (€-70.96 Million ≈ $-82.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Adaptimmune Therapeutics plc (2016–2024)
Cash flow conversion efficiency of Adaptimmune Therapeutics plc from 2016 to 2024. This chart illustrates how Adaptimmune Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Adaptimmune Therapeutics plc for real-time trading data and today's change.
Adaptimmune Therapeutics plc Cash Flow Conversion Ratio Explained
Adaptimmune Therapeutics plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Adaptimmune Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adaptimmune Therapeutics plc ranked by their cash flow conversion efficiency. Also see Adaptimmune Therapeutics plc (473A) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oceanpal Inc
NASDAQ:OP
|
-0.007x |
|
MeVis Medical Solutions AG
XETRA:M3V
|
0.005x |
|
OS Therapies Incorporated
NYSE MKT:OSTX
|
-1.000x |
|
Corentec Co Ltd
KQ:104540
|
0.100x |
|
Solytech Enterprise Corp
TW:1471
|
-0.002x |
|
Golden House
TA:GOHO
|
0.010x |
|
Shinil Electronics Co
KO:002700
|
-0.059x |
|
BII Railway Transportation Technology Holdings Company Limited
F:CN6
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Adaptimmune Therapeutics plc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Adaptimmune Therapeutics plc from 2016 to 2024. Review 473A cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €11.85 Million ≈ $13.85 Million |
€-73.21 Million ≈ $-85.59 Million |
-6.178x | -73.28% |
| 2023-12-31 | €39.51 Million ≈ $46.19 Million |
€-140.88 Million ≈ $-164.70 Million |
-3.565x | -105.92% |
| 2022-12-31 | €81.88 Million ≈ $95.72 Million |
€-141.77 Million ≈ $-165.74 Million |
-1.731x | -3423.82% |
| 2021-12-31 | €205.96 Million ≈ $240.79 Million |
€10.73 Million ≈ $12.54 Million |
0.052x | +133.17% |
| 2020-12-31 | €341.23 Million ≈ $398.93 Million |
€-53.59 Million ≈ $-62.65 Million |
-0.157x | +82.74% |
| 2019-12-31 | €123.64 Million ≈ $144.55 Million |
€-112.51 Million ≈ $-131.53 Million |
-0.910x | -115.21% |
| 2018-12-31 | €246.88 Million ≈ $288.63 Million |
€-104.39 Million ≈ $-122.04 Million |
-0.423x | -58.01% |
| 2017-12-31 | €202.98 Million ≈ $237.31 Million |
€-54.31 Million ≈ $-63.50 Million |
-0.268x | +7.70% |
| 2016-12-31 | €166.14 Million ≈ $194.24 Million |
€-48.17 Million ≈ $-56.31 Million |
-0.290x | -- |
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatmen… Read more